MX2017004684A - Compuestos neuroactivos y metodos de uso de los mismos. - Google Patents

Compuestos neuroactivos y metodos de uso de los mismos.

Info

Publication number
MX2017004684A
MX2017004684A MX2017004684A MX2017004684A MX2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A MX 2017004684 A MX2017004684 A MX 2017004684A
Authority
MX
Mexico
Prior art keywords
methods
neuroactive compounds
sterol
subject
disorder
Prior art date
Application number
MX2017004684A
Other languages
English (en)
Inventor
Martinez Botella Gabriel
C Quirk Michael
J Doherty James
Original Assignee
Sage Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sage Therapeutics Inc filed Critical Sage Therapeutics Inc
Publication of MX2017004684A publication Critical patent/MX2017004684A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00

Abstract

Se proporcionan métodos para tratar un paciente que padece de un trastorno de síntesis de esterol o un trastorno de deficiencia de esterol, por ejemplo, síndrome Smith-Lemli-Opitz, el método comprende administrar al sujeto una cantidad efectiva de un compuesto que modula el receptor NMDA.
MX2017004684A 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos. MX2017004684A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201462060932P 2014-10-07 2014-10-07
PCT/US2015/054551 WO2016057713A1 (en) 2014-10-07 2015-10-07 Neuroactive compounds and methods of use thereof

Publications (1)

Publication Number Publication Date
MX2017004684A true MX2017004684A (es) 2017-06-30

Family

ID=55653736

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2017004684A MX2017004684A (es) 2014-10-07 2015-10-07 Compuestos neuroactivos y metodos de uso de los mismos.
MX2021011939A MX2021011939A (es) 2014-10-07 2017-04-07 Compuestos neuroactivos y metodos de uso de los mismos.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021011939A MX2021011939A (es) 2014-10-07 2017-04-07 Compuestos neuroactivos y metodos de uso de los mismos.

Country Status (18)

Country Link
US (2) US20170304321A1 (es)
EP (1) EP3204011A4 (es)
JP (3) JP2017530982A (es)
KR (1) KR20170065637A (es)
CN (2) CN112121171A (es)
AU (2) AU2015330906A1 (es)
BR (1) BR112017007053A2 (es)
CA (1) CA2963938C (es)
IL (2) IL292465A (es)
MX (2) MX2017004684A (es)
MY (1) MY202135A (es)
NZ (1) NZ730862A (es)
PE (1) PE20170907A1 (es)
PH (1) PH12017500639A1 (es)
RU (1) RU2764702C2 (es)
SG (2) SG11201702799UA (es)
WO (1) WO2016057713A1 (es)
ZA (1) ZA201702545B (es)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107936076B (zh) 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
JP6255082B2 (ja) 2013-03-13 2017-12-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびその使用方法
CN105073728A (zh) 2013-03-15 2015-11-18 全球血液疗法股份有限公司 化合物及其用于调节血红蛋白的用途
EA201992707A1 (ru) 2013-11-18 2020-06-30 Глобал Блад Терапьютикс, Инк. Соединения и их применения для модуляции гемоглобина
PL3639828T3 (pl) 2013-12-24 2022-05-02 Virginia Commonwealth University Zastosowanie utlenowanych siarczanów cholesterolu (ocs) w leczeniu ostrej niewydolności wątroby
EP3157528B1 (en) 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
AU2016289965B2 (en) 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
KR20180026742A (ko) 2015-07-06 2018-03-13 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
JP2018519351A (ja) 2015-07-06 2018-07-19 セージ セラピューティクス， インコーポレイテッド オキシステロールおよびそれらの使用の方法
BR112018070123A2 (pt) 2016-04-01 2019-02-05 Sage Therapeutics Inc oxiesterós e métodos de uso dos mesmos
WO2017193046A1 (en) 2016-05-06 2017-11-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
LT3481846T (lt) 2016-07-07 2021-08-25 Sage Therapeutics, Inc. 11-pakeistieji 24-hidroksisteroliai, skirti naudoti gydant su nmda susijusias būkles
EP4101861A1 (en) * 2016-08-02 2022-12-14 Virginia Commonwealth University Compositions comprising 5-cholesten-3, 25-diol, 3-sulfate (25hc3s) or pharmaceutically acceptable salt thereof and at least one cyclic oligosaccharide
MA46351A (fr) 2016-09-30 2021-06-02 Sage Therapeutics Inc Oxystérols substitués en c7 et procédés en tant que modulateurs nmda
KR20230051723A (ko) 2016-10-18 2023-04-18 세이지 테라퓨틱스, 인크. 옥시스테롤 및 그의 사용 방법
CN115181153A (zh) 2016-10-18 2022-10-14 萨奇治疗股份有限公司 氧甾醇及其使用方法
EP3335730A1 (en) * 2016-12-15 2018-06-20 Fundació Institut de Recerca Biomédica de Bellvitge (IDIBELL) Compounds for treating x-linked adrenoleukodystrophy
US10857163B1 (en) 2019-09-30 2020-12-08 Athenen Therapeutics, Inc. Compositions that preferentially potentiate subtypes of GABAA receptors and methods of use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5376645A (en) 1990-01-23 1994-12-27 University Of Kansas Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
WO2006037016A2 (en) * 2004-09-27 2006-04-06 The Regents Of The University Of California Novel therapy for treatment of chronic degenerative brain diseases and nervous system injury
CA2703497A1 (en) * 2007-11-06 2009-05-14 N.V. Organon A method of hormone suppression in humans
EP2296658A4 (en) * 2008-05-09 2014-01-15 Univ Emory ANTAGONISTS OF NMDA RECEPTORS USEFUL FOR THE TREATMENT OF NEUROPSYCHIATRIC DISORDERS
WO2010065709A2 (en) * 2008-12-03 2010-06-10 Amin Khan Hydroxamic acid derivatives, preparation and therapeutic uses thereof
US20110319416A1 (en) * 2009-01-28 2011-12-29 Emory University Subunit Selective NMDA Receptor Antagonists For The Treatment Of Neurological Conditions
WO2011028794A2 (en) * 2009-09-01 2011-03-10 Lazarus Therapeutics, Inc. Treatment of huntington's disease with cycloserine and an nmda receptor antagonist
KR101692275B1 (ko) * 2010-02-11 2017-01-04 노오쓰웨스턴 유니버시티 ２차 구조 안정화된 ｎｍｄａ 수용체 조절제 및 그의 용도
US20120035156A1 (en) * 2010-08-09 2012-02-09 Daniela Alberati Combination of glyt1 compound with antipsychotics
CN107936076B (zh) * 2011-09-08 2021-10-15 萨奇治疗股份有限公司 神经活性类固醇、组合物、及其用途
US20150119327A1 (en) * 2012-04-25 2015-04-30 The Regents Of The University Of California Drug screening platform for rett syndrome
WO2014025942A1 (en) * 2012-08-09 2014-02-13 Emory University Nmda receptor modulators and uses related thereto
SG11201505934XA (en) * 2013-01-29 2015-09-29 Naurex Inc Spiro-lactam nmda receptor modulators and uses thereof
BR112015022934A8 (pt) 2013-03-13 2019-11-26 Sage Therapeutics Inc esteróides neuroativos, composições e usos destes
JP6255082B2 (ja) 2013-03-13 2017-12-27 セージ セラピューティクス， インコーポレイテッド 神経刺激性ステロイドおよびその使用方法
EP3157528B1 (en) * 2014-06-18 2023-09-13 Sage Therapeutics, Inc. Oxysterols and methods of use thereof
US10238664B2 (en) * 2014-07-09 2019-03-26 Duke University Compositions and methods for the repair of myelin
AU2016289965B2 (en) * 2015-07-06 2021-09-09 Sage Therapeutics, Inc. Oxysterols and methods of use thereof

Also Published As

Publication number Publication date
PE20170907A1 (es) 2017-07-12
AU2015330906A1 (en) 2017-04-27
MY202135A (en) 2024-04-05
NZ730862A (en) 2024-01-26
SG10202011773UA (en) 2021-01-28
CN112121171A (zh) 2020-12-25
US20170304321A1 (en) 2017-10-26
JP2017530982A (ja) 2017-10-19
IL251505A0 (en) 2017-05-29
IL251505B (en) 2022-05-01
SG11201702799UA (en) 2017-05-30
CA2963938C (en) 2023-10-24
RU2017115849A3 (es) 2019-05-15
IL292465A (en) 2022-06-01
PH12017500639A1 (en) 2017-09-25
JP2020196759A (ja) 2020-12-10
EP3204011A4 (en) 2018-06-20
AU2021200721B2 (en) 2023-06-01
BR112017007053A2 (pt) 2018-06-19
CN107405352A (zh) 2017-11-28
ZA201702545B (en) 2019-06-26
RU2764702C2 (ru) 2022-01-19
CA2963938A1 (en) 2016-04-14
WO2016057713A1 (en) 2016-04-14
AU2021200721A1 (en) 2021-03-04
RU2017115849A (ru) 2018-11-13
JP2022033285A (ja) 2022-02-28
MX2021011939A (es) 2021-11-03
US20230218638A1 (en) 2023-07-13
KR20170065637A (ko) 2017-06-13
EP3204011A1 (en) 2017-08-16

Similar Documents

Publication Publication Date Title
MX2021011939A (es) Compuestos neuroactivos y metodos de uso de los mismos.
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12017500692A1 (en) Antibody molecules to pd-l1 and uses thereof
PH12016501966B1 (en) Compounds and compositions as toll-like receptor 7 agonists
MX2021008113A (es) Composiciones farmaceuticas que comprenden un antagonista de il-4r para usarse en el tratamiento del asma.
MX2015012478A (es) Metodos y composiciones para inhibicion de proteinas que contienen bromodominio.
PH12014502704B1 (en) Compounds and compositions for modulating egfr activity
MX2017014191A (es) Metodos de tratamiento de una enfermedad neurodegenerativa.
GB2541571A (en) Pharmaceutical compositions
NZ737399A (en) Ccr2 modulators
WO2016100619A3 (en) Treatment and diagnosis of cancer
PH12016501366A1 (en) Novel anti-baff antibodies
TW201713333A (en) Methods of treating a neurodegenerative disease
MX2014011103A (es) Moduladores del receptor x del higado.
MX2016004540A (es) Tiazolopirimidinonas como moduladores de la actividad de receptores de n-metil-d-aspartato (nmda).
NZ715582A (en) Lectin-like oxidized ldl receptor 1 antibodies and methods of use
EA201491894A1 (ru) Способы лечения непереносимости лактозы
IN2014KN02993A (es)
PH12016502244A1 (en) Hsp70 modulators and methods for making and using the same
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
TN2016000177A1 (en) P-substituted asymmetric ureas and medical uses thereof
MX371343B (es) Moduladores del receptor x hepatico (lxr).
MX2016015298A (es) Inhibidores de nampt y metodos.
NZ724799A (en) Compositions and methods for the treatment or prevention of neurodegenerative disorders
NZ750581A (en) Compositions and methods for treating neurodegenerative diseases and cardiomyopathy